Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine
Third Quarter 2026 Total Revenues of $110.0 million
Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)%
Third Quarter 2026 Adjusted Net Loss of $18.7 million
Third Quarter 2026 Gross
Appointment of Frank Vargo, VP, Treasurer, to Interim CFO effective January 1, 2027
Emergent BioSolutions Inc. (NYSE:EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer,
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the third quarter of 2026.
Participants can access the
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE:EBS). Such investors are advised to
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE:EBS). Such investors are
Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) --
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE:EBS). Such investors are
Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03,
GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and
Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE:EBS). Such investors are advised to
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE:EBS). Such investors are
Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. ("Emergent BioSolutions" or the "Company") (NYSE: EBS) investors concerning the Company’s possible
